Quest Diagnostics Incorporated (DGX)
$195.00
$-2.76
(-1.40%)
As on 18-Jun-2026 16:12EDT
Market cap
$21,586 Mln
Revenue (TTM)
$11,278 Mln
P/E Ratio
21.5
P/B Ratio
2.9
Div. Yield
1.7 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$770 Mln
-
ROE
0.1 %
-
ROCE
7.1 %
-
Industry P/E
39.49
-
EV/EBITDA
12.4
-
Debt to Equity
0.7
-
Book Value
$--
-
EPS
$9.1
-
Face value
--
-
Shares outstanding
110,696,429
10 Years Aggregate
CFO
$13,663.00 Mln
EBITDA
$17,322.00 Mln
Net Profit
$9,502.00 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Quest Diagnostics (DGX)
| 12.4 | 4.5 | -1.8 | 9.0 | 12.1 | 8.8 | 9.9 |
|
BSE Sensex*
| -9.3 | 2.0 | 0.1 | -5.7 | 6.6 | 8.0 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Quest Diagnostics (DGX)
| 15.0 | 9.3 | -11.9 | -9.6 | 47.9 | 14.1 | 31.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Quest Diagnostics (DGX)
|
195.0 | 21,585.8 | 11,278.0 | 1,024.0 | 14.7 | 13.3 | 21.5 | 2.9 |
| 98.3 | 125,449.2 | 407,905.0 | 2,932.0 | 1.6 | 3.9 | 43.1 | 1.6 | |
| 207.9 | 13,344.7 | 13,835.1 | 781.4 | 14.3 | -- | 20 | 21.6 | |
| 98.0 | 9,724.5 | 6,066.4 | 609.2 | 18.6 | 16.7 | 16.8 | 3.9 | |
| 375.2 | 83,227.6 | 76,388.0 | 6,794.0 | 15.8 | -- | 12.9 | 291.3 | |
| 35.5 | 8,209.8 | 2,369.7 | -13.2 | -1.6 | -2.6 | -- | 18.4 | |
| 255.8 | 20,977.2 | 14,144.2 | 941.5 | 9.7 | 10.8 | 22.7 | 2.4 | |
| 172.6 | 14,864.7 | 21,455.0 | 1,703.0 | 18.6 | 17.1 | 9 | 3.1 | |
| 153.7 | 8,730.0 | 5,274.0 | 363.4 | 9.2 | 16.2 | 24.3 | 3.7 | |
| 141.2 | 8,545.9 | 17,760.3 | 1,520.8 | 12.2 | 20.2 | 5.9 | 1.1 |
Shareholding Pattern
View DetailsAbout Quest Diagnostics (DGX)
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing,... and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey. Read more
-
Chairman, CEO & President
Mr. James E. Davis
-
Executive VP & CFO
Mr. Sam A. Samad
-
Headquarters
Secaucus, NJ
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Quest Diagnostics (DGX)
What is the current share price of Quest Diagnostics Incorporated (DGX) Today?
The share price of Quest Diagnostics Incorporated (DGX) is $195.00 (NYSE) as of 18-Jun-2026 16:12 EDT. Quest Diagnostics Incorporated (DGX) has given a return of 12.05% in the last 3 years.
What is the current PB & PE ratio of Quest Diagnostics Incorporated (DGX)?
The P/E ratio of Quest Diagnostics Incorporated (DGX) is 21.55 times as on 18-Jun-2026, a 45 discount to its peers’ median range of 39.49 times.
The P/B ratio of Quest Diagnostics Incorporated (DGX) is 2.93 times as on 18-Jun-2026, a 5 discount to its peers’ median range of 3.08 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
19.59
|
2.71
|
|
2024
|
19.57
|
2.52
|
|
2023
|
18.24
|
2.47
|
|
2022
|
19.02
|
3.05
|
|
2021
|
10.84
|
3.36
|
What is the 52 Week High and Low of Quest Diagnostics Incorporated (DGX)?
The 52-week high and low of Quest Diagnostics Incorporated (DGX) are Rs 213.50 and Rs 164.65 as of 20-Jun-2026.
What is the market cap of Quest Diagnostics Incorporated (DGX)?
Quest Diagnostics Incorporated (DGX) has a market capitalisation of $ 21,586 Mln as on 18-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Quest Diagnostics Incorporated (DGX)?
Before investing in Quest Diagnostics Incorporated (DGX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.